Application of obeticholic acid in preparation of medicine for preventing and / or treating acute pancreatitis
Through gavage or intraperitoneal injection of obecolic acid, the death of acinar cells induced by cholecystotin and sodium taurocholate is reduced, and the mitochondrial reactive oxygen level is reduced, which solves the problem of pancreatic acinar cell necrosis in acute pancreatitis, significantly improves the Pancreatic tissue and seroenzymatic indicators demonstrate their preventive and therapeutic potential in AP.
Patent Information
- Application Number
- CN202310634973.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-31
- Publication Date
- 2024-12-03
AI Technical Summary
There is no clear drug to alleviate pancreatic acinar cell necrosis in acute pancreatitis (AP), and the function of obecocholic acid (OCA) in AP is unknown.
Obeloccholic acid is used as a drug, and through gavage or intraperitoneal injection, it significantly reduces acinar cell death induced by cholecystotin and sodium taurocholate, reduces mitochondrial reactive oxygen level, and improves pancreatic tissue damage and seroenzyme levels.
In acute pancreatitis and severe acute pancreatitis models, obebiccholic acid significantly improves pancreatic tissue damage and seroenzymatic indicators, reduces inflammatory factors, and shows its potential for preventing and treating AP.
Smart Images

Figure CN119055661A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of biomedicine technology, and specifically relates to the use of obeticholic acid (OCA) in the preparation of a drug for preventing and / or treating acute pancreatitis. Background Art
[0002] Acute pancreatitis (AP) is an inflammatory disease caused by premature activation of zymogens, which can lead to self-digestion of the pancreas. Most AP cases are mild and generally only require conservative treatment. However, some patients may develop severe acute pancreatitis (SAP), which manifests as local or surrounding pancreatic tissue necrosis, as well as distant organ dysfunction, such as acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), and shock. The mortality rate of SAP can be as high as 40%-70%. Current studies have shown that pancreatic acinar cell necrosis is one of the important mechanisms for the development of AP, and pancreatic acinar cell necrosis is closely related to the severity and prognosis of AP. However, in clinical practice, there is no clear drug to alleviate AP necrosis.
[0003] Bile acids are derived from cholesterol molecules and are amphiphilic substances with both hydrophilic and lipophilic properties. The two most abundant primary bile acids in humans are cholic acid and chenodeoxycholic acid. Intestinal bacteria metabolize primary bile acids into secondary bile acids, namely lithocholic acid and deoxycholic acid, by 7-dehydroxylase. Typically, bile acids are conjugated with taurine or glycine to form at least eight different types of bile acids. In rodents, taurine conjugation is predominant, and therefore, the major bile acids in mouse bile are taurocholic acid and taurodeoxycholic acid. Bile acids with fewer hydroxyl groups undergo sulfation and glucuronidation, which are required for their detoxification. Bile acids are biosynthesized via the classical (neutral) or alternative (acidic) pathways. The neutral pathway, initiated by CYP7A1, dominates bile acid biosynthesis in adults and begins with the 7-hydroxylation of cholesterol. The alternative pathway of BA biosynthesis begins with the cytochrome P450 enzyme CYP27A1, followed by oxidized sterol 7α-hydroxylase. In recent years, it has been found that bile acids can act as signaling molecules dependent on receptors, regulating a variety of downstream metabolic, inflammatory, immune and other pathological and physiological processes. Recent studies on patients with Alzheimer's disease (a neurodegenerative disease) and multiple sclerosis (an inflammatory demyelinating disease of the central nervous system) have found that low levels of circulating bile acid metabolites are closely associated with the development of cognitive impairment and can affect astrocyte neurotoxicity and pro-inflammatory polarization of microglia. In addition, in a group of patients with metabolic diseases, obesity and diabetes are both associated with lower serum bile acid (HCA) concentrations, and serum HCA levels are a strong predictor of the occurrence of metabolic diseases within 5 and 10 years26. Guo et al. found that bile acids can reduce the severity of many inflammatory diseases, such as the LPS-induced sepsis model. By inhibiting the production of inflammatory mediators by macrophages, secondary metabolites of bile acids (such as deoxycholic acid) have significant anti-inflammatory effects. Experiments have confirmed that supplementation with taurodeoxycholic acid (TUDCA) and ursodeoxycholic acid (UDCA) has shown protective effects in various animal models of neurodegeneration.
[0004] However, the function of obeticholic acid (OCA) in AP is still unknown, and there are no reports on the preventive and therapeutic effects of obeticholic acid (OCA) in acute pancreatitis. Summary of the invention
[0005] The object of the present invention is to provide the use of obeticholic acid in the preparation of a medicament for preventing and / or treating acute pancreatitis.
[0006] In order to achieve the above object, the present invention adopts the following technical solutions:
[0007] The present invention discloses for the first time the use of obeticholic acid in preparing a medicine for preventing and / or treating acute pancreatitis.
[0008] Preferably, the drug is a drug for improving pancreatic tissue damage.
[0009] Further preferably, the pancreatic tissue damage includes edema, inflammatory exudate and acinar cell necrosis.
[0010] More preferably, the drug is a drug that reduces cholecystokinin-induced acinar cell death by obeticholic acid.
[0011] More preferably, the drug is a drug that significantly reduces the level of mitochondrial reactive oxygen species in acinar cells induced by cholecystokinin through obeticholic acid.
[0012] More preferably, the drug is a drug that reduces sodium taurocholate-induced acinar cell death through obeticholic acid.
[0013] Preferably, the drug is a drug that improves serum enzymology and serum amylase levels.
[0014] Preferably, the drug is administered by intragastric or intraperitoneal injection.
[0015] The present invention also discloses the use of obeticholic acid in preparing a medicine for preventing and / or treating severe acute pancreatitis.
[0016] The present invention also discloses a medicine for preventing and / or treating pancreatitis, acute pancreatitis or severe acute pancreatitis, which is prepared by adding or not adding pharmaceutically acceptable excipients to obeticholic acid.
[0017] Compared with the prior art, the present invention has the following beneficial effects:
[0018] The present invention discloses a new pharmaceutical use of obeticholic acid in acute pancreatitis or severe acute pancreatitis. The method simulates two clinically relevant acute pancreatitis models, namely, a mouse acute pancreatitis model induced by caerulein and a mouse severe acute pancreatitis model induced by retrograde injection of sodium taurocholate into the pancreatic duct, and experimentally verifies that administration of obeticholic acid OCA by oral gavage or intraperitoneal injection can significantly improve the occurrence and development of acute pancreatitis or severe acute pancreatitis involved in the above two models, thus indicating that obeticholic acid can be expected to be used in the clinical prevention / treatment of AP.
[0019] Furthermore, the present invention has verified through experiments that obeticholic acid alleviates the symptoms of AP by improving pancreatic tissue damage, as well as improving serum enzymology and serum amylase levels.
[0020] Furthermore, the present invention clarifies the dosage for experimental mice by oral administration and intraperitoneal injection, and the optimal dosage is 20 mg / kg. BRIEF DESCRIPTION OF THE DRAWINGS
[0021] Figure 1The figures show that intraperitoneal injection of different concentrations of obeticholic acid (OCA) in Example 1 can significantly improve pancreatic damage (edema, inflammatory exudation, necrosis) in mice with acute pancreatitis induced by caerulein; wherein, A is a pathological image of HE staining of pancreatic tissue in mice; and B is a statistical graph of pancreatic injury pathological score.
[0022] Figure 2 This is a graph showing the results of Example 1 in which intraperitoneal injection of different concentrations of obeticholic acid (OCA) can reduce serum amylase and serum lipase levels in mice with acute pancreatitis induced by caerulein; wherein A is the serum amylase level; and B is the serum lipase level.
[0023] Figure 3 The figure shows that intraperitoneal injection of different concentrations of obeticholic acid (OCA) in Example 1 can reduce the levels of serum inflammatory factors in mice with acute pancreatitis induced by caerulein; wherein A is the level of serum interleukin 6 (IL-6); B is the level of serum tumor necrosis factor α (TNFα); and C is the level of serum monocyte chemoattractant protein 1 (MCP-1).
[0024] Figure 4 The optimal dose of obeticholic acid (OCA) intraperitoneal injection in Example 2 can significantly improve pancreatic injury (edema, inflammatory exudation, necrosis) in mice with severe acute pancreatitis induced by retrograde injection of sodium taurocholate; wherein A is a pathological image of HE staining of pancreatic tissue in mice; B is a statistical graph of pancreatic injury pathological score.
[0025] Figure 5 This is the result graph showing that intraperitoneal injection of the optimal dose of obeticholic acid (OCA) in Example 2 can reduce serum amylase and serum lipase levels in mice with severe acute pancreatitis induced by retrograde injection of sodium taurocholate; wherein A is the serum amylase level; B is the serum lipase level.
[0026] Figure 6 The results of intragastric administration of the optimal dose of obeticholic acid (OCA) in Example 3 can significantly improve pancreatic damage (edema, inflammatory exudation, necrosis) in mice with acute pancreatitis induced by caerulein; wherein, A is a pathological image of HE staining of pancreatic tissue in mice; B is a statistical graph of pancreatic injury pathological score.
[0027] Figure 7 This is a graph showing the results of intragastric administration of the optimal dose of obeticholic acid (OCA) in Example 3 to reduce serum amylase and serum lipase levels in mice with acute pancreatitis induced by caerulein; wherein A is the serum amylase level; B is the serum lipase level.
[0028] Figure 8 This is a graph showing the results of Example 4 showing that different concentrations of obeticholic acid (OCA) can reduce the level of LDH release in acinar cell damage induced by cholecystokinin (CCK) in vitro.
[0029] Fig. 9 The results of PI fluorescence staining showing that the optimal dose of obeticholic acid (OCA) in Example 4 can reduce in vitro acinar cell necrosis; wherein A is a PI staining fluorescence image of cells in the acinar cell injury model induced by OCA treatment; and B is a fluorescence quantification image.
[0030] Fig.10 This is the result of JC-1 fluorescence staining showing that the optimal dose of obeticholic acid (OCA) in Example 5 can reduce the mitochondrial membrane potential of acinar cells in vitro.
[0031] Fig.11 This is the result of fluorescence staining of MitoROS, the reactive oxygen species in mitochondria of acinar cells in vitro, at the optimal dose of obeticholic acid (OCA) in Example 5.
[0032] Fig.12 This is the result graph showing that the optimal dose of obeticholic acid (OCA) in Example 6 can reduce the level of LDH release in acinar cell damage induced by sodium taurocholate (TLCS) in vitro. DETAILED DESCRIPTION
[0033] In order to enable those skilled in the art to better understand the scheme of the present invention, the technical scheme in the embodiments of the present invention will be clearly and completely described below in conjunction with the drawings in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work should fall within the scope of protection of the present invention.
[0034] It should be noted that the terms "first", "second", etc. in the specification and claims of the present invention and the above-mentioned drawings are used to distinguish similar objects, and are not necessarily used to describe a specific order or sequence. It should be understood that the data used in this way can be interchanged where appropriate, so that the embodiments of the present invention described herein can be implemented in an order other than those illustrated or described herein. In addition, the terms "including" and "having" and any variations thereof are intended to cover non-exclusive inclusions, for example, a process, method, system, product or device that includes a series of steps or units is not necessarily limited to those steps or units that are clearly listed, but may include other steps or units that are not clearly listed or inherent to these processes, methods, products or devices.
[0035] The present invention is further described in detail below in conjunction with the accompanying drawings:
[0036] The experimental methods used in the examples of the present invention are conventional methods unless otherwise specified. The reagents and materials used in the examples can be purchased conventionally, and the quantitative experiments involved in the examples are repeated at least three times, and the results are averaged.
[0037] The C57 / BL6 mice used were purchased from the Model Animal Center of Nanjing University.
[0038] The caerulein used was purchased from MCE Company with the product number HY-A0190.
[0039] The cholecystokinin (CCK) used was purchased from Sigma-Aldrich with the catalog number T6515.
[0040] The taurocholate sodium (TLCS) used was purchased from MCE Company with the product number HY-137255.
[0041] The obeticholic acid (OCA) used was purchased from MCE Company with the product number HY-12222.
[0042] Example 1: Application of intraperitoneal injection of obeticholic acid (OCA) in the prevention / treatment of acute pancreatitis I. Acute pancreatitis model induced by caerulein in mice
[0043] Experimental animals: 6-8 week old male C57BL / 6J mice (weight 20-25 g).
[0044] The experimental animals were divided into a normal control group and a cerulein model group. The model group mice were intraperitoneally injected with cerulein (100ug / kg, 1h interval, 10 injections continuously) to establish an acute pancreatitis model. The control group mice were given a strict PBS control intraperitoneal injection.
[0045] 2. Intraperitoneal injection of obeticholic acid (OCA)
[0046] Mice in the caerulein model group were randomly divided into AP (Caerulein) group and obeticholic acid OCA (5mg / kg, 10mg / kg, 20mg / kg, 40mg / kg) treatment group, with 6 mice in each group. OCA (dissolved in 10% DMSO solution) was intraperitoneally injected 3h after caerulein modeling, and the AP group was given the same 10% DMSO solvent for strict control. All mice were anesthetized by intraperitoneal injection of sodium pentobarbital 12h after the first intraperitoneal injection of caerulein, and the mouse serum was collected for serum enzyme levels. Subsequently, the mice underwent in vivo cardiac perfusion to remove the circulating blood, and the pancreatic tissue was quickly extracted for fixation and dehydration, and HE-stained paraffin sections and immunohistochemical staining were made.
[0047] The results are as follows Figure 1 , Figure 2 and Figure 3As shown in the figure, it can be seen that different concentrations of OCA can significantly improve pancreatic tissue damage (edema, inflammatory exudation and acinar cell necrosis), improve serum enzymes and serum amylase levels, and reduce serum inflammatory factor levels. The 20 mg / kg OCA treatment group had the best effect. The above results suggest that intraperitoneal injection of OCA may improve or alleviate the occurrence and development of acute pancreatitis. * represents a significant difference P < 0.05, ** represents a significant difference P < 0.01, and *** represents a significant difference P < 0.001.
[0048] Example 2: Application of intraperitoneal injection of obeticholic acid (OCA) in the prevention / treatment of severe acute pancreatitis
[0049] 1. Severe acute pancreatitis model in mice induced by retrograde injection of sodium taurocholate into the pancreatic duct
[0050] Experimental animals: 6-8 weeks old C57 / BL6 male mice (weight 20-25 g)
[0051] The experimental animals were divided into sham operation group, model group and obeticholic acid (OCA) (20 mg / kg) treatment group (10 animals in each group).
[0052] 1. The experimental animals were anesthetized by intraperitoneal injection of sodium pentobarbital (injected according to body weight, 8 μL / g).
[0053] 2. All experimental animals were anesthetized and fixed on the operating table. After laparotomy in the model group, surgical forceps were used to bluntly separate and expose the bile and pancreatic ducts, clamp the upper common bile duct, and retrogradely inject 100 μL of 1% sodium taurocholate at the opening of the duodenal papilla. The abdominal cavity was closed layer by layer and the skin was sutured. The sham operation group only underwent laparotomy and laparotomy related operations, and no retrograde injection of the pancreatic duct was performed. All mice recovered for 30 minutes on a 37°C constant temperature operating table after surgery.
[0054] 2. Intraperitoneal injection of obeticholic acid (OCA)
[0055] The treatment group was intraperitoneally injected with OCA (dissolved in 10% DMSO solution) at 3h, the AP group was given the same 10% DMSO solvent for strict control, and the sham-operated mice were intraperitoneally injected with 10% DMSO solution. All mice were anesthetized by intraperitoneal injection of sodium pentobarbital 12h after the start of modeling, and the mouse serum was collected for serum enzyme levels. Subsequently, the mice underwent in vivo cardiac perfusion to remove the circulating blood, and the pancreatic tissue was quickly extracted for fixation and dehydration, and paraffin sections and immunohistochemical staining for HE staining were made.
[0056] The results are as follows Figure 4 As shown in Figures A and B, 20 mg / kg OCA can significantly improve pancreatic tissue damage (pancreatic tissue edema, inflammatory exudate, and acinar cell necrosis) in mice injected with sodium taurocholate (TLCS) via retrograde duct injection. Figure 5 As shown in A and B, OCA can improve serum enzymology and serum amylase levels.
[0057] Example 3: Application of intragastric administration of obeticholic acid (OCA) in the prevention / treatment of acute pancreatitis 1. Acute pancreatitis model induced by caerulein in mice
[0058] Experimental animals: 6-8 week old male C57BL / 6J mice (weight 20-25 g).
[0059] The experimental animals were divided into a normal control group and a cerulein model group. The model group mice were intraperitoneally injected with cerulein (100 μg / kg, 1 hour interval, 10 injections continuously) to establish an acute pancreatitis model. The control group mice were given a strict PBS control intraperitoneal injection.
[0060] 2. Intragastric administration of obeticholic acid (OCA)
[0061] Mice in the caerulein model group were randomly divided into an AP (Caerulein) group and an obeticholic acid (OCA) (20 mg / kg) treatment group, with 6 mice in each group. OCA (dissolved in 10% DMSO solution) was administered intragastrically 3 hours after caerulein modeling, and the AP group was given the same 10% DMSO solvent for strict control. All mice were anesthetized by intraperitoneal injection of sodium pentobarbital 12 hours after the first intraperitoneal injection of caerulein, and the mouse serum was collected for serum enzyme levels. Subsequently, the mice underwent in vivo cardiac perfusion to remove the circulating blood, and the pancreatic tissue was quickly extracted for fixation and dehydration, and HE-stained paraffin sections and immunohistochemical staining were made.
[0062] The results are as follows Figure 6 and Figure 7 As shown in the figure, it can be seen that oral administration of 20 mg / kg OCA can significantly improve pancreatic tissue damage (edema, inflammatory exudation and acinar cell necrosis), improve serum enzymology and serum amylase levels. The above results suggest that oral administration of OCA can also improve or alleviate the occurrence and development of acute pancreatitis. * represents a significant difference P < 0.05, ** represents a significant difference P < 0.01, and *** represents a significant difference P < 0.001.
[0063] Example 4: Application of OCA in reducing acinar cell death in vitro (CCK-induced acinar cell injury model)
[0064] Primary acinar cells: Pancreatic acinar cells were extracted from 6-8 week old C57 / BL6 male mice, seeded in six-well plates, and stably cultured in 1M Hepes medium (containing 10% FBS) at 37 degrees Celsius in a 5% CO2 incubator. CCK was administered to establish an in vitro cell injury model (6 hours).
[0065] The specific groups are as follows:
[0066] Control group: cultured for 6 hours;
[0067] CCK group: 5 μM cholecystokinin (CCK) was added to each well and cultured for 6 h;
[0068] CCK+OCA group: 5 μM cholecystokinin (CCK) and different concentration gradients of OCA (1 μM, 2.5 μM, 5 μM) were added to each well and cultured for 6 hours.
[0069] Cells from each group were collected and tested for lactate dehydrogenase (LDH) damage. Figure 8 As shown, it can be seen that different concentrations of OCA significantly alleviated the death of acinar cells induced by CCK, among which 2.5μM OCA had the best protective effect. * represents a significant difference P < 0.05, ** represents a significant difference P < 0.01, and *** represents a significant difference P < 0.001.
[0070] The cells in each group were collected and stained with propidium iodide (PI) to detect cell necrosis.
[0071] The results are as follows Fig. 9 As shown, it can be seen that 2.5 μM OCA significantly alleviated CCK-induced acinar cell death, and the number of necrotic cells positively marked by PI staining was significantly reduced.
[0072] Example 5: Application of OCA in enhancing mitochondrial function of acinar cells in vitro (CCK-induced acinar cell injury model)
[0073] Primary acinar cells: Pancreatic acinar cells were extracted from 6-8 week old C57 / BL6 male mice, inoculated in six-well plates, and stably cultured in 1M Hepes medium (containing 10% FBS) at 37 degrees Celsius in a 5% CO2 incubator. CCK was administered to establish an in vitro cell injury (6h) model.
[0074] The specific groups are as follows:
[0075] Control group: cultured for 6 hours;
[0076] CCK group: 5 μM cholecystokinin (CCK) was added to each well and cultured for 6 h;
[0077] CCK+OCA group: 5 μM cholecystokinin (CCK) and different concentration gradient OCA (2.5 μM) were added to each well and cultured for 6 hours.
[0078] Cells from each group were collected and mitochondrial membrane potential JC-1 and mitochondrial reactive oxygen species MitROS fluorescence staining were performed. Fig.10 As shown in Figure 2, 2.5 μM OCA significantly enhanced CCK-induced mitochondrial function in acinar cells. Fig.11As shown, it can be seen that 2.5 μM OCA significantly reduced the level of mitochondrial reactive oxygen species in acinar cells induced by CCK.
[0079] Example 6: Application of OCA in reducing acinar cell death in vitro (TLCS-induced acinar cell injury model)
[0080] Primary acinar cells: Pancreatic acinar cells were extracted from 6-8 week old C57 / BL6 male mice, seeded in six-well plates, and stably cultured in 1M Hepes medium (containing 10% FBS) at 37 degrees Celsius in a 5% CO2 incubator. TLCS was administered to establish an in vitro cell injury model (6 hours).
[0081] The specific groups are as follows:
[0082] Control group: cultured for 6 hours;
[0083] TLCS group: 1 mM sodium taurocholate (TLCS) was added to each well and cultured for 6 hours;
[0084] TLCS+OCA group: 1 mM sodium taurocholate (TLCS) and different concentration gradients of OCA (2.5 uM) were added to each well and cultured for 6 hours.
[0085] The cells in each group were collected and analyzed for lactate dehydrogenase (LDH) damage.
[0086] The results are as follows Fig.12 As shown, it can be seen that 2.5 μM OCA significantly alleviated TLCS-induced acinar cell death.
[0087] The above contents are only for explaining the technical idea of the present invention and cannot be used to limit the protection scope of the present invention. Any changes made on the basis of the technical solution in accordance with the technical idea proposed by the present invention shall fall within the protection scope of the claims of the present invention.
Claims
1. Use of obeticholic acid in the preparation of a medicament for preventing and / or treating acute pancreatitis.
2. The use according to claim 1, characterized in that The medicine is a medicine for improving pancreatic tissue damage.
3. The use according to claim 2, characterized in that The pancreatic tissue damage includes edema, inflammatory exudate and acinar cell necrosis.
4. The use according to claim 3, characterized in that The drug is a drug that reduces cholecystokinin-induced acinar cell death through obeticholic acid.
5. The use according to claim 3, characterized in that The drug is a drug that significantly reduces the mitochondrial reactive oxygen level of acinar cells induced by cholecystokinin through obeticholic acid.
6. The use according to claim 3, characterized in that The drug is a drug that reduces the acinar cell death induced by sodium taurocholate through obeticholic acid.
7. The use according to claim 1, characterized in that The medicine is a medicine for improving serum enzymology and serum amylase levels.
8. The use according to claim 1, characterized in that The drug is administered by intragastric or intraperitoneal injection.
9. Use of obeticholic acid in the preparation of a drug for preventing and / or treating severe acute pancreatitis.
10. A drug for preventing and / or treating pancreatitis, acute pancreatitis or severe acute pancreatitis, characterized in that: It is prepared by adding or not adding pharmaceutically acceptable excipients to obeticholic acid.
Citation Information
Cited By
Application of obeticholic acid in prevention and treatment of acute hepatopancreatic necrosis of prawns
CN119950519A
Use of obeticholic acid in prevention and treatment of acute hepatopancreas necrosis disease in prawn
CN119950519B
Construction method of diabetic mouse model after chronic pancreatitis
CN121080456A
